IPO registrations (S-1, F-1) · Registrants
NewcelX Ltd.
- SEC CIK
- 1783036 · filings on EDGAR ↗
- Name on the registration
- NLS Pharmaceutics Ltd.
- Former names
- NLS Pharmaceutics Ltd. (2019–2025)
- Registration
- Form F-1, first filed 2020-02-28, last 2025-09-25; 7 initial registrations, 6 amendments
- Outcome
- Final prospectus filed 2021-02-01; declared effective 2021-01-28
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- V8
- Business address
- THE CIRCLE 6, 8058, Zurich
- Ticker
- NCEL (Nasdaq)
- EDGAR entity type
- other
- Insiders and CEO pay
- NewcelX Ltd. on the corporate pages
Offering terms
- Proposed price range
- $5.00–$6.00 per share (F-1/A filed 2021-01-20)
- Final price
- $4.15 per share, below the range (424B4 filed 2021-02-01, an initial public offering)
- Shares sold
- 4,819,277
- Gross proceeds
- $20,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol NLSP
- Lead underwriters
- Maxim Group
- Syndicate
- Brookline Capital Markets; Number of Units Maxim Group LLC (4,337,349); Brookline Capital Markets, a division of Arcadia Securities, LLC (481,928)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form D issuer: NewcelX Ltd. EXACT (CIK (EXACT))
- SEC filer: NewcelX Ltd. EXACT (CIK (EXACT))
Filings 34
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2020-02-28 | F-1 | F-1 (foreign registration) | NLS Pharmaceutics Ltd. | 0001213900-20-005070 ↗ |
| 2020-08-31 | F-1/A | F-1/A (amendment) | NLS Pharmaceutics Ltd. | 0001213900-20-024460 ↗ |
| 2020-10-19 | F-1/A | F-1/A (amendment) | NLS Pharmaceutics Ltd. | 0001213900-20-031906 ↗ |
| 2020-11-13 | F-1/A | F-1/A (amendment) | NLS Pharmaceutics Ltd. | 0001213900-20-036675 ↗ |
| 2020-11-17 | F-1/A | F-1/A (amendment) | NLS Pharmaceutics Ltd. | 0001213900-20-037777 ↗ |
| 2021-01-20 | F-1/A | F-1/A (amendment) | NLS Pharmaceutics Ltd. | 0001213900-21-002942 ↗ |
| 2021-01-28 | EFFECT | EFFECT (declared effective) | NLS Pharmaceutics Ltd. | 9999999995-21-000316 ↗ |
| 2021-02-01 | 424B4 | 424B4 (final prospectus) | NLS Pharmaceutics Ltd. | 0001213900-21-005637 ↗ |
| 2021-06-04 | EFFECT | EFFECT (declared effective) | NLS Pharmaceutics Ltd. | 9999999995-21-002210 ↗ |
| 2021-10-01 | EFFECT | EFFECT (declared effective) | NLS Pharmaceutics Ltd. | 9999999995-21-003735 ↗ |
| 2021-10-22 | F-1 | F-1 (foreign registration) | NLS Pharmaceutics Ltd. | 0001213900-21-054182 ↗ |
| 2021-11-01 | F-1/A | F-1/A (amendment) | NLS Pharmaceutics Ltd. | 0001213900-21-055655 ↗ |
| 2021-11-03 | EFFECT | EFFECT (declared effective) | NLS Pharmaceutics Ltd. | 9999999995-21-004183 ↗ |
| 2021-12-20 | F-1 | F-1 (foreign registration) | NLS Pharmaceutics Ltd. | 0001213900-21-066320 ↗ |
| 2022-01-06 | EFFECT | EFFECT (declared effective) | NLS Pharmaceutics Ltd. | 9999999995-22-000079 ↗ |
| 2022-02-11 | EFFECT | EFFECT (declared effective) | NLS Pharmaceutics Ltd. | 9999999995-22-000432 ↗ |
| 2022-06-10 | F-1 | F-1 (foreign registration) | NLS Pharmaceutics Ltd. | 0001213900-22-032265 ↗ |
| 2022-06-21 | EFFECT | EFFECT (declared effective) | NLS Pharmaceutics Ltd. | 9999999995-22-001834 ↗ |
| 2022-12-15 | EFFECT | EFFECT (declared effective) | NLS Pharmaceutics Ltd. | 9999999995-22-003560 ↗ |
| 2023-01-20 | EFFECT | EFFECT (declared effective) | NLS Pharmaceutics Ltd. | 9999999995-23-000153 ↗ |
| 2024-05-30 | F-1 | F-1 (foreign registration) | NLS Pharmaceutics Ltd. | 0001213900-24-047585 ↗ |
| 2024-06-25 | EFFECT | EFFECT (declared effective) | NLS Pharmaceutics Ltd. | 9999999995-24-001948 ↗ |
| 2024-08-27 | F-1 | F-1 (foreign registration) | NLS Pharmaceutics Ltd. | 0001213900-24-072968 ↗ |
| 2024-11-26 | EFFECT | EFFECT (declared effective) | NLS Pharmaceutics Ltd. | 9999999995-24-003585 ↗ |
| 2025-09-09 | EFFECT | EFFECT (declared effective) | NLS Pharmaceutics Ltd. | 9999999995-25-002886 ↗ |
| 2025-09-25 | F-1 | F-1 (foreign registration) | NLS Pharmaceutics Ltd. | 0001213900-25-091697 ↗ |
| 2025-09-30 | EFFECT | EFFECT (declared effective) | NLS Pharmaceutics Ltd. | 9999999995-25-003252 ↗ |
| 2025-11-18 | EFFECT | EFFECT (declared effective) | NewcelX Ltd. | 9999999995-25-003309 ↗ |
| 2025-11-18 | EFFECT | EFFECT (declared effective) | NewcelX Ltd. | 9999999995-25-003312 ↗ |
| 2026-05-06 | EFFECT | EFFECT (declared effective) | NewcelX Ltd. | 9999999995-26-001512 ↗ |
| 2026-05-15 | EFFECT | EFFECT (declared effective) | NewcelX Ltd. | 9999999995-26-001675 ↗ |
| 2026-06-17 | EFFECT | EFFECT (declared effective) | NewcelX Ltd. | 9999999995-26-002036 ↗ |
| 2026-08-26 | EFFECT | EFFECT (declared effective) | NewcelX Ltd. | 9999999995-26-002774 ↗ |
| 2026-09-22 | EFFECT | EFFECT (declared effective) | NewcelX Ltd. | 9999999995-26-003024 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021-01-20 | F-1/A | registration statement | $5.00–$6.00 | 3,636,363 | - | Nasdaq NLSP | 2 | primary document; range, shares headline, cover names 2 | document ↗ | |
| 2021-02-01 | 424B4 | final prospectus | $4.15 | 4,819,277 | $20,000,000 | Nasdaq NLSP | 4 | primary document; price sentence, shares headline, proceeds table, underwriting table 2, cover names 2 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Galili Tamar | Director | 1 | 2026 | ||
| Hagai Omri | Officer | Chief Financial Officer | 1 | 2026 | |
| Iohan Eran Israel | Director | 1 | 2026 | ||
| Molakandov Kfir | Officer | VP of R&D | 1 | 2026 | |
| Oren Liora | Director | 1 | 2026 | ||
| Revel Michel | Director,Officer; Director,Officer,TenPercentOwner | CSO and Director | 2 | 2026 | |
| Samuel Olivier | Director | 2 | 2026 | ||
| Twito Ronen | Director,Officer | Chairman and CEO | 1 | 2026 | |
| Zwyer Alexander | Director | 1 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2026-08-24 | NewcelX Ltd. | Biotechnology | $2,940,234 | $2,940,234 | 5 | 1 |
| 2026-05-13 | NewcelX Ltd. | Biotechnology | $3,428,989 | $3,428,989 | 4 | 1 |
| 2025-07-10 | NLS Pharmaceutics Ltd. | Pharmaceuticals | $1,000,000 | $1,000,000 | 3 | 1 |
| 2025-04-14 | NLS Pharmaceutics Ltd. | Pharmaceuticals | $2,000,000 | $2,000,000 | 3 | 1 |
| 2025-01-22 | NLS Pharmaceutics Ltd. | Pharmaceuticals | $499,999 | $499,999 | 1 | 1 |
| 2024-10-21 | NLS Pharmaceutics Ltd. | Pharmaceuticals | $7,200,000 | $7,200,000 | 6 | 1 |
| 2024-07-15 | NLS Pharmaceutics Ltd. | Pharmaceuticals | $786,660 | $786,660 | 2 | 1 |
| 2024-04-03 | NLS Pharmaceutics Ltd. | Pharmaceuticals | $1,750,000 | $1,750,000 | 2 | 1 |
| 2022-12-21 | NLS Pharmaceutics Ltd. | Pharmaceuticals | $30,000,000 | $10,000,000 | 4 | 1 |
| 2022-10-14 | NLS Pharmaceutics Ltd. | Pharmaceuticals | $4,000,000 | $4,000,000 | 5 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | NewcelX Ltd. | Form D private offerings | CIK (EXACT) | |
| SEC filer | NewcelX Ltd. | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.